Corbus Pharmaceuticals Holdings, Inc. (CRBP): Price and Financial Metrics
GET POWR RATINGS... FREE!
CRBP POWR Grades
- Growth is the dimension where CRBP ranks best; there it ranks ahead of 79.09% of US stocks.
- CRBP's strongest trending metric is Quality; it's been moving up over the last 206 days.
- CRBP's current lowest rank is in the Stability metric (where it is better than 5.71% of US stocks).
CRBP Stock Summary
- As for revenue growth, note that CRBP's revenue has grown -89.07% over the past 12 months; that beats the revenue growth of only 1.69% of US companies in our set.
- In terms of volatility of its share price, CRBP is more volatile than 99.01% of stocks we're observing.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for CRBP comes in at -92.66% -- higher than that of only 2.95% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Corbus Pharmaceuticals Holdings Inc are ARCT, MTEM, BBI, JNCE, and PIRS.
- Visit CRBP's SEC page to see the company's official filings. To visit the company's web site, go to www.corbuspharma.com.
CRBP Stock Price Chart Interactive Chart >
CRBP Price/Volume Stats
|Current price||$1.67||52-week high||$9.78|
|Prev. close||$1.39||52-week low||$0.91|
|Day high||$1.75||Avg. volume||10,802,281|
|50-day MA||$1.88||Dividend yield||N/A|
|200-day MA||$2.54||Market Cap||208.81M|
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Company Bio
Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases. The company is based in Norwood, Massachusetts.
CRBP Latest News Stream
|Loading, please wait...|
CRBP Latest Social Stream
View Full CRBP Social Stream
Latest CRBP News From Around the Web
Below are the latest news stories about Corbus Pharmaceuticals Holdings Inc that investors may wish to consider to help them evaluate CRBP as an investment opportunity.
Norwood, MA, May 11, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be presenting at three upcoming virtual investor conferences. The following are the details for the conferences: 2021 RBC Capital Markets Global Healthcare Conference Event: Fireside Chat Discussion and Q&ADate and Time: Tuesday, May 18, 2021, at 3:40pm EST Oppenheimer Rare & Orphan Disease Summit Event: Fireside Chat Discussion and Q&ADate and Time: Friday, May 21, 2021, at 9:55am EST Jefferies Virtual Global Healthcare Conference Event: Fireside Chat Discussion an...
Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Photo by Andrew Brookes/Cultura via Getty ImagesWe wrote about Corbus Pharmaceuticals (NASDAQ:CRBP) back in January and stated that the recent unsuccessful Lenabasum phase 3 and phase 2 trials would not end up being a death sentence for the firm. Expectations were very high before the result which meant a soft...
Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
Topline data on schedule for Q2 2021Dermatomyositis is a rare and life-threatening autoimmune disease characterized by skin and muscle inflammation, and affects ~80,000 people in North America, EU, and JapanThere is a significant need for safer and more effective treatments in dermatomyositis because of limitations of current treatment options Norwood, MA, March 30, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that the last subject completed the final visit in the double-blind, placebo-controlled part of the Company’s Phase 3 DETERMINE study of lenabasum for the treatment of dermatomyositis. Th...
GAINERS: SugarBud Craft Growers (PINK: RLLRF ) shares closed up 26.19% at $0.05 Cipher Pharms Inc (PINK: CPHRF ) shares closed up 17.11% at $0.89 Chemesis International (PINK: CADMF ) shares closed up 16.82% at $0.71 CANADA HOUSE WELLNESS GRP (OTC: SARSF ) shares closed up 15.62% at $0.04 GTEC Holdings (OTCQB: GGTTF ) shares closed up 14.2% at $0.72 Zynerba Pharmaceuticals (NASDAQ: ZYNE ) shares closed up 9.94% at $5.31 Corbus Pharmaceuticals (NASDAQ: CRBP ) shares closed up 8.8% at $2.35 Tetra Bio Pharma (OTCQB: TBPMF ) shares closed up 8.02% at $0.16 GrowGeneration (NASDAQ: GRWG ) shares closed up 7.94% at $54.78 High Tide (OTCQB: HITIF ) shares closed up 6.27% … Full story available on Benzinga.com
CRBP Price Returns
Continue Researching CRBPHere are a few links from around the web to help you further your research on Corbus Pharmaceuticals Holdings Inc's stock as an investment opportunity:
Corbus Pharmaceuticals Holdings Inc (CRBP) Stock Price | Nasdaq
Corbus Pharmaceuticals Holdings Inc (CRBP) Stock Quote, History and News - Yahoo Finance
Corbus Pharmaceuticals Holdings Inc (CRBP) Stock Price and Basic Information | MarketWatch